8-K: Moleculin Biotech CEO Highlights Annamycin's Potential in AML Treatment

Moleculin Biotech's CEO, Walter Klemp, discussed the significant progress of their drug candidate Annamycin in treating relapsed or refractory Acute Myeloid Leukemia (AML) during a virtual investor call.

Summary

• Moleculin Biotech held a virtual investor call to discuss their progress, particularly with their drug candidate Annamycin.
• The company's STAT3 inhibitor program, WP1066, is advancing with an IV formulation, and preliminary data showed clinical improvement in children with DIPG.
• Discussions are underway with research institutions to fund further development of the antimetabolite program, WP1122 and WP1096, but the primary focus is on Annamycin.
• Annamycin's development shifted from a single agent to a combination therapy with Cytarabine (AnnAraC), leading to increased patient enrollment and complete responses.
• The company expects to provide an update on the AML trial recruitment and results along with year-end numbers in late March.
• The unmet need in AML remains significant, with more than half of patients lacking effective treatment options.
• Annamycin has shown a 40% Complete Response (CR) rate and a 47% CR/CRi rate in a Phase 2 clinical trial, which is higher than any approved drug for relapsed or refractory AML.
• The company plans to begin a pivotal approval trial before the end of the year with more than 100 patients.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment due to the promising clinical trial results for Annamycin and the company's plans for a pivotal trial. The CEO's confidence and the comparison to existing therapies suggest a strong potential for success.

Positives

• The WP1066 program has shown clinical improvement in children with DIPG.
• The shift to combination therapy with Annamycin has led to increased patient enrollment and complete responses.
• Annamycin's CR rate of 40% is higher than any approved drug for relapsed or refractory AML.
• The company is planning a pivotal trial for Annamycin, a major milestone for any biotech company.

Negatives

• The oral version of WP1066 had bioavailability challenges.
• The Annamycin data is based on a small sample size of 15 patients.
• The current trial is a Phase 2a trial, not an approval trial.

Risks

• The Annamycin data is preliminary and based on a small sample size, and the results may not be replicated in the larger pivotal trial.
• The company needs to successfully complete the pivotal trial to gain approval for Annamycin.
• There is no guarantee that the pivotal trial will track the results seen so far.

Future Outlook

Moleculin plans to begin a pivotal approval trial for Annamycin before the end of the year, and they will provide further updates on the AML trial and year-end numbers in late March. The company also plans to discuss the trial design, FDA and EMA process, and timeline in the next part of the investor series.

Management Comments

• The public does not understand the importance of the data we have recently announced and the significance of what will happen this year.
• Our clear priority is to push Annamycin over the finish line, so almost all our internal resources are focused only on Annamycin.
• Clinicians started to see the real potential for Annamycin and began enrolling more and more patients who were 2nd or 3rd line instead of 5th line or greater.
• We think this presents a huge opportunity for Annamycin to significantly impact patients lives and to generate returns for our investors.
• If the investing public really understood where we are right now, our stock price would be significantly greater than it currently is.
• Just getting into a pivotal trial is a massive milestone for any biotech company.

Industry Context

The discussion highlights the significant unmet need in AML treatment, even with recent drug approvals. The success of Venetoclax and the acquisition of Vyxeos demonstrate the market potential for effective AML therapies. Moleculin is positioning Annamycin to address this unmet need, potentially capturing a significant market share.

Comparison to Industry Standards

• Venetoclax, approved for combination use in AML in 2019, generates $2 billion in annual revenue for AbbVie.
• Jazz Pharma acquired Vyxeos for $1.5 billion, a drug used in a subset of AML patients.
• The average 5-year survival rate for AML patients over 20 is just 28%.
• The CR rate of 40% for Annamycin is nearly double the performance of the majority of existing 2nd line therapies that have been approved so far.

Stakeholder Impact

• Shareholders may see a positive impact due to the promising results of Annamycin and the potential for future revenue.
• Patients with AML may benefit from a new and potentially more effective treatment option.
• Employees may experience increased job security and growth opportunities due to the company's progress.

Next Steps

• Moleculin will provide an update on the AML trial recruitment and results along with year-end numbers in late March.
• The company plans to begin a pivotal approval trial for Annamycin before the end of the year.
• Moleculin will discuss the trial design, FDA and EMA process, and timeline in the next part of the investor series.

Key Dates

Keywords

Annamycin, AML, Acute Myeloid Leukemia, Cancer Therapy, Clinical Trial, Drug Development, Biotech, WP1066, WP1122, STAT3 inhibitor, Cytarabine, AnnAraC, Complete Response, CR, CRi